Search results for: Michael Lee
Filter search results
19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
4 June 2013
Since 1993, OHE has hosted an annual lecture given by an eminent economist or clinician on an important current issue. In 2012, Professor Sir Michael Rawlins spoke on challenges and…
What constitutes credible evidence of effectiveness
1 June 2013
In this monograph based his remarks at the 19th OHE Annual Lecture, Professor Sir Michael Rawlins examines the standards of proof required to show the effectiveness of a medical therapy….
OHE Welcomes Professors Rawlins and Smith to its Policy Board
6 May 2013
…1960s. In April, Professor Sir Michael Rawlins and Professor Peter C Smith joined the group. Composed of academics and thought leaders from within and outside of the UK, OHE’s Policy…
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development
4 October 2016, 11:00pm
OHE lunchtime seminar with Leeza Osipenko (NICE Scientific Advice), Nancy Delvin and François Maignen (OHE) Health Technology Assessment (HTA) scientific advice (SA) was created by the National Institute for Health…
OHE Lunchtime Seminar and Webinar: The UK Biotech Sector and Brexit: Past Performance and Future Prospects
2 November 2017, 12:00am
OHE Lunchtime Seminar with Sir Geoffrey Owen, London School of Economics , and Professor Michael Hopkins, SPRU – the Science Policy Research Unit, in the School of Business, Management and…
OHE Lunchtime Seminar: The UK Biotech Sector and Brexit: Past Performance and Future Prospects
25 September 2017
OHE Lunchtime Seminar with Sir Geoffrey Owen and Professor Michael Hopkins. The biotech sector of the US has enjoyed a success that the UK sector has found difficult to match….
Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
20 January 2015
Jon Sussex presents on the opportunity costs of implementing NICE decisions in Wales, and OHE attend HESG in Leeds, January 2015. Opportunity costs of implementing NICE decisions in NHS Wales…
Cost and Benefits of Pharmaceutical Research
1 May 1987
…as part of a vear of celebration to mark the Silver Jubilee of OHE. The whole subject of medical innovation has been central to the development of the National Health…
Comparing Preference-based Outcome Measures for Overactive Bladder: EQ-5D-5L vs OAB-5D
31 January 2018
A recent paper examines EQ-5D-5L outcomes in patients with overactive bladder and compares them to results on the OAB-5D, a condition-specific measure. A new journal article by OHE’s Michael Herdman…